Single Domain Antibodies Targeting CD33 for AML Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for acute myeloid leukemia (AML) are limited, with a need for novel targeted treatments due to the disease's complexity and the lack of effective therapies.

Innovation Solution

Development of novel antibodies specifically targeting CD33, a protein frequently expressed on AML cells, including monoclonal antibodies and chimeric antigen receptors (CARs) to selectively bind and treat AML and associated malignancies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional therapies are used for AML, then treatment options are limited, but the lack of effective targeted therapies remains a challenge

Engineering Contradiction:

Improvetreatment optionsVSAvoideffectiveness of therapy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent develops novel anti-CD33 antibodies with specific amino acid sequences that change the binding parameters and affinity to CD33 antigen on AML cells, providing improved therapeutic effectiveness compared to conventional therapies

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite therapeutic approaches by combining anti-CD33 antibodies with chimeric antigen receptors (CARs) that express these antibodies, forming a multi-component therapeutic system that enhances both adaptability and reliability of treatment

Inventive Principle:

Principle #40Composite materials

2Weight of moving object

If single domain antibodies are used instead of full antibodies, then the antibody size is reduced, but the binding affinity and stability may be compromised

Engineering Contradiction:

Improveantibody sizeVSAvoidbinding affinity

Core Design Contradiction:

Weight of moving objectVSReliability

Solution Approach 1:

The patent optimizes the local quality of the single domain antibody by specifically designing the CDR regions (complementarity determining regions) with precise amino acid sequences to ensure high binding affinity to CD33, while keeping the overall antibody structure compact and small in size

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The invention changes the structural parameters of the antibody by using only the variable heavy chain domain (VHH) without light chains or constant regions, reducing the molecular weight while maintaining functional binding capability through optimized CDR sequences

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20230365675A1Single domain antibodies against CD33

Publication Date: 2023.11.16 VOR BIOPHARMA INC

AI summary

The present disclosure includes antibodies that specifically CD33, as well as methods of making and using such antibodies.